Document Detail

Blockade of EMAP II Protects Cardiac Function after Chronic Myocardial Infarction by Inducing Angiogenesis.
MedLine Citation:
PMID:  25456857     Owner:  NLM     Status:  Publisher    
Promoting angiogenesis is a key therapeutic target for protection from chronic ischemic cardiac injury. Endothelial-Monocyte-Activating-Polypeptide-II (EMAP II) protein, a tumor-derived cytokine having anti-angiogenic properties in cancer, is markedly elevated following myocardial ischemia. We examined whether neutralization of EMAP II induces angiogenesis and has beneficial effects on myocardial function and structure after chronic myocardial infarction (MI). EMAP II antibody (EMAP II AB), vehicle, or non-specific IgG (IgG) was injected ip at 30min and 3, 6, and 9days after permanent coronary artery occlusion in mice. EMAP II AB, compared with vehicle or non-specific antibody, significantly, p<0.05, improved the survival rate after MI, reduced scar size and attenuated the development of heart failure, i.e., left ventricular ejection fraction was significantly higher in EMAP II AB group, fibrosis was reduced by 24%, and importantly, more myocytes were alive in EMAP II AB group in the infarct area. In support of an angiogenic mechanism, capillary density (193/HPF vs. 172/HPF), doubling of the number of proliferating endothelial cells, and angiogenesis related biomarkers were upregulated in mice receiving EMAP II AB treatment as compared to IgG. Furthermore, EMAP II AB prevented EMAP II protein inhibition of in vitro tube formation in HUVECs. We conclude that blockade of EMAP II induces angiogenesis and improves cardiac function following chronic MI, resulting in reduced myocardial fibrosis and scar formation and increased capillary density and preserved viable myocytes in the infarct area.
Chujun Yuan; Lin Yan; Pallavi Solanki; Stephen F Vatner; Dorothy E Vatner; Margaret A Schwarz
Related Documents :
24373377 - Value of speckle-tracking echocardiography and mri-based feature tracking analysis in a...
24294037 - Validation of the vitronectin knockout mouse as a model for studying myocardial infarct...
22140597 - Reference values for echocardiographic parameters and indexes of left ventricular funct...
24961617 - Prevalence of abnormal ecgs in male soccer players decreases with the seattle criteria,...
18626627 - Natriuretic peptides in acute pulmonary embolism: a systematic review.
6702687 - Ventricular arrhythmias in aortic valve disease: analysis of 102 patients.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-29
Journal Detail:
Title:  Journal of molecular and cellular cardiology     Volume:  -     ISSN:  1095-8584     ISO Abbreviation:  J. Mol. Cell. Cardiol.     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  0262322     Medline TA:  J Mol Cell Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014. Published by Elsevier Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Information structure and organisation in change of shift reports: An observational study of nursing...
Next Document:  Spin Crossover in Tetranuclear Fe(II) Complexes, {[(tpma)Fe(?-CN)]4}X4 (X = ClO4(-), BF4(-)).